Top > Search of International Patents > MALARIA VACCINE

MALARIA VACCINE

Foreign code F160008821
File No. (S2015-0054-N0)
Posted date Aug 10, 2016
Country WIPO
International application number 2015JP075275
International publication number WO 2016059911
Date of international filing Sep 6, 2015
Date of international publication Apr 21, 2016
Priority data
  • P2014-213247 (Oct 17, 2014) JP
Title MALARIA VACCINE
Abstract The present invention addresses the problem of providing a malaria vaccine exhibiting a higher protective effect than that of conventional malaria vaccines. The present invention was perfected due to the discovery that, after a recombinant virus other than a baculovirus that includes a gene encoding an amino acid sequence of a malaria antigen, plasmid DNA that has a gene encoding an amino acid sequence of this malaria antigen introduced thereto, or a protein that has an amino acid sequence of this malaria antigen is administered to a patient, administering to the patient a recombinant baculovirus that includes a gene encoding an amino acid sequence of this malaria antigen and a gene encoding an amino acid sequence of DAF results in a high protective effect being exhibited.
Outline of related art and contending technology BACKGROUND ART
(Malaria) malaria is, infected with a malaria parasite infection transmitted by the anopheles, infected with 2 million each year, 60 million or more people are dead. An ideal measure malaria infection, inoculation of the vaccine is effective. However, vaccine development has been extensive efforts even though, not yet been put to practical use. Malaria is, has a complex life cycle, life stage in one of the further 1-diverse antigen. These and vaccine development and may be very difficult. Current, a measure for the effect of malaria, the pesticide can be mixed and subjected to treatment in the mosquito net artemisinin-based sleep (ACT: artemisinin-based combination therapy) in. However, mosquitoes herbicide resistance, resistance to artemisinin and also reports the appearance of protozoa, quickly malaria vaccine has been a need to develop (reference: non-patent document 1).
Method (a method of treatment of malaria) the treatment of malaria, particularly malaria vaccine with respect to, the following is reported.
Patent Document 1 (Patent Document 1) is, 'one vertebrate promoter, the promoter of the baculovirus connected to the other of the dual, downstream of the promoter, the viral particle of the component with the at least one gene encoding a protein and may be, at least one immunogenic foreign gene can be coupled with a fusion gene containing characterized, dual, promoter fuzed to a gene transfer vector which includes the structure manufacturing method of the' has been disclosed. However, the patent document 1, 'the configuration of the malaria vaccine of the present invention as well as recombinant baculovirus, decay accelerating factor (DAF) or interleukin 12 (IL-12) carrying a' does not suggest or disclose.
Patent Document 2 (Patent Document 2) is, 'recombinant Autographa californica nuclear polyhedrosis virus (AcNPV) as an active ingredient of the pharmaceutical composition, is the recombinant AcNPV, and at least the polyhedrin promoter and is connected to a dual CAG under control of a promoter containing a fusion gene of any of the following and, the pharmaceutical composition' has been disclosed. However, Patent Document 2 is, 'the configuration of the malaria vaccine of the present invention as well as recombinant baculovirus, carries a DAF' does not suggest or disclose.
Patent Document 3 (Patent Document 3) is, 'virus (a) a nucleotide sequence coding the foreign envelope proteins, the coding sequence of the envelope and (b) operatively connected to the first promoter 1, (c) a nucleotide sequence encoding the antigen protein, (d) The antigen coding sequence is operatively coupled to the first recombinant baculovirus promoters 2' has been disclosed. However, Patent Document 3 is, 'malaria vaccine of the present invention as well as the configuration of the recombinant baculovirus, or DAF be carrying IL-12' does not suggest or disclose.
Non-patent document 2 (non-patent document 2) is, 'Priming-boosting method, after the vaccination with vaccinia vaccine (ChAd63) stimulators (MVA) by the inoculation of the protective effect is malaria infection has reached the 40%' - diones. However, non-patent document 2 is, 'the configuration of the malaria vaccine of the present invention as well as recombinant baculovirus, or DAF IL-12 carries a' does not suggest or disclose.
Non-patent document 3 (non-patent document 3) is, 'FP9-CS(fowlpox virus recombinant virus incorporating CSP) after the vaccination with MVA-CS(vaccinia recombinant virus incorporating CSP to) by the inoculation of the protective effect is malaria infection has reached the 90%' - diones. However, in the method described in non-patent document 3, and the adjuvant used, if the adjuvant was not used, the protective effect is reduced to 35% malaria infection. Further, the non-patent document 3, 'malaria vaccine of the present invention as well as the configuration of the recombinant baculovirus, or DAF be carrying IL-12' does not suggest or disclose.
Thus, the current malaria infection protective effect is insufficient, there can be further improved.
Scope of claims (In Japanese)[請求項1]
以下を含む組換えバキュロウイルスを含むマラリアワクチンであって、
(1)マラリア抗原のアミノ酸配列をコードする遺伝子及びDAFのアミノ酸配列をコードする遺伝子、又は、マラリア抗原のアミノ酸配列をコードする遺伝子、
(2)該遺伝子を発現可能なプロモーター、
さらに、該組換えバキュロウイルスは、該マラリア抗原のアミノ酸配列をコードする遺伝子を含むバキュロウイルス以外の組換えウイルス、該マラリア抗原のアミノ酸配列をコードする遺伝子が導入されたプラスミドDNA、又は該マラリア抗原のアミノ酸配列を有するタンパク質を患者に投与した後に、該患者に投与することを特徴とする、
該組換えバキュロウイルスを含むマラリアワクチン。
[請求項2]
前記組換えバキュロウイルスは、以下のいずれか1の組換えバキュロウイルスと併用投与することを特徴とする、請求項1に記載のマラリアワクチン、
(1)IL-12のアミノ酸配列をコードする遺伝子及び該遺伝子を発現可能なプロモーターを含む組換えバキュロウイルス、
(2)IL-12のアミノ酸配列をコードする遺伝子及びDAFのアミノ酸配列をコードする遺伝子並びに該遺伝子を発現可能なプロモーター。
[請求項3]
以下の2つの組換えバキュロウイルスを含むマラリアワクチン、
(1)マラリア抗原のアミノ酸配列をコードする遺伝子及びDAFのアミノ酸配列をコードする遺伝子若しくはマラリア抗原のアミノ酸配列をコードする遺伝子、並びに該遺伝子を発現可能なプロモーターを含む組換えバキュロウイルス、
(2)IL-12のアミノ酸配列をコードする遺伝子及びDAFのアミノ酸配列をコードする遺伝子若しくはIL-12のアミノ酸配列をコードする遺伝子、並びに該遺伝子を発現可能なプロモーターを含む組換えバキュロウイルス。
[請求項4]
前記マラリア抗原が、CSPである請求項1~3のいずれか1に記載のマラリアワクチン。
[請求項5]
前記バキュロウイルス以外の組換えウイルスは、組換えアデノウイルスである請求項1~4のいずれか1に記載のマラリアワクチン。
[請求項6]
以下のいずれか1に記載のマラリアワクチン組成物。
(1)請求項1~5のいずれか1に記載のマラリアワクチン、並びにマラリア抗原のアミノ酸配列をコードする遺伝子及び該遺伝子を発現可能なプロモーターを含む組換えアデノウイルス
(2)請求項1~5のいずれか1に記載のマラリアワクチン、並びにIL-12のアミノ酸配列をコードする遺伝子及び該遺伝子を発現可能なプロモーターを含む組換えバキュロウイルス
(3)請求項1~5のいずれか1に記載のマラリアワクチン、並びに、IL-12のアミノ酸配列をコードする遺伝子及びDAFのアミノ酸配列をコードする遺伝子並びに該遺伝子を発現可能なプロモーターを含む組換えバキュロウイルス
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY
  • Inventor
  • YOSHIDA,Shigeto
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close